MiRank: A bioinformatics tool for gene/miRNA ranking and pathway profiling with TCGA–KEGG data sets

Siddharth G. Reddy^{1,2}, Weimin Xiao², and Preethi H. Gunaratne²

¹Phillips Exeter Academy, Exeter, New Hampshire 03833, USA ²Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204, USA

Project hosting: http://code.google.com/p/miranktool

Abstract

The Cancer Genome Atlas (TCGA) provides researchers with clinicopathological data and genomic characterizations of various carcinomas. These data sets include expression microarrays for genes and microR-NAs – short, non-coding strands of RNA that downregulate gene expression through RNA interference – as well as days_to_death and days_to_last_followup fields for each tumor sample. Our aim is to develop a software tool that screens TCGA data sets for genes/miRNAs with functional involvement in specific cancers. Furthermore, our computational pipeline is intended to produce a set of visualizations, or profiles, that place our screened outputs in a pathway-centric context.

We accomplish our 'screening' by ranking genes/miRNAs by the correlation of their expression misregulation with differential patient survival. In other words, if a gene/miRNA is consistently misregulated in patients with poor survival rates and, on the other hand, is expressed more 'normally' in patients with longer survival rates, then it is ranked highly; if its misregulation has no such correlation with good/bad survival in patients, then its rank is low. Our pathway profiling pipeline produces several outputs, which allow us to examine the functional roles played by highly ranked genes discovered by our screening.

Running the OV (ovarian serous cystadenocarcinoma) data set through our analysis pipeline, we find that several highly ranked pathways and functional groups of genes (VEGF, Jun, Fos, etc.) have already been shown to play some part in the development of epithelial ovarian carcinomas. We also observe that several top-ranking miRNAs target oncogenes in the top two quartiles of our rank-ordered list, implying that our ranking scheme is sound in principle and effectively sorts genes/miRNAs by their functional involvement in cancer.

Our outputs suggest that the dysfunction of the Wnt signaling pathway, which regulates cell-fate specification and progenitor cell differentiation, has a disproportionate impact on the survival of ovarian cancer patients. This work has immediate implications: (1) efficient cancer diagnostics with microarrays for highly ranked genes/miRNAs in Wnt, and (2) novel drug treatments that target Wnt as well as other highly ranked pathways and functional groups of genes. It also motivates the improvement of MiRank to take into consideration the network of interactions between gene products and the optimization of node selection by cancer, a disease that evolves to selectively misregulate certain genes in order to lead a cell through tumorigenesis.

Contents

1	Intr	roduction	3
2	Met	thods	4
	2.1	Expression Misregulation Metric X	4
	2.2	MiRank-A	5
		2.2.1 Survival Spreads	5
		2.2.2 Log-Rank Matrices	6
		2.2.3 Rank Spread	7
		2.2.4 Expression-Survival Correlation Statistic T	8
	2.3	MiRank-B	8
		2.3.1 Patient Grouping	8
		2.3.2 Expression and Correlation Statistics	9
		2.3.3 Recombination	10
		2.3.4 Expression-Survival Correlation Statistic M	11
	2.4	MiRank-C	11
		2.4.1 Survival Analysis	11
		2.4.2 Cox Proportional-Hazards Model	12
		2.4.3 Cox Regression	12
		2.4.4 Gradient Descent with Modification	13
	2.5	Pathway Profiling	14
		2.5.1 Consolidated Rank α	14
		2.5.2 KEGG Pathway Enrichment	14
		2.5.3 Clustering	16
		2.5.4 Partitioning	16
		2.5.5 GO Term Enrichment	17
3	\mathbf{Res}	sults	17
	3.1	Gene/miRNA Ranking	17
	3.2	Prognostic Index Performance Comparison	17
	3.3	Pathway Profiling	18
4	Dis	cussion	18
-	4.1	Ontology Overview of Top-Ranking Pathways	18
	4.2	Ontology of Top-Ranking Genes	20
	4.3	Oncogenic Targets of Top-Ranking miRNAs	21
	4.4	Intra-pathway "Driver" Genes	21
5	Cor	nclusion	21

1 Introduction

The use of computational tools to elucidate the mechanisms underlying the genetic, misregulatory aspect of cancer is intended to relieve the often tedious efforts made by wet-lab biologists to identify 'significant' genes and microRNAs by knock-out analysis. The goal of our pipeline is to allow researchers to screen cancer data sets for genes and miRNAs that are more likely to experimentally validate, leaving more time for investigation into molecular mechanisms less amenable to quantitative, bioinformatics analysis.

Most scripts developed for computational research in cancer biology are designed to predict clinicopathological features of tumors based on gene expression profiles. Such profiles are typically optimized to identify sets of genes whose expression is highly correlated with patient survival, tumor grade, chemotherapy sensitivity, etc.

We postulate that the genes in expression profiles optimized for survival prediction in cancer patients are functionally implicated in the disease. Similarly, we propose that ranking genes by the correlation of their expression misregulation with differential patient survival will result in an ordering that reflects the extent of each gene's functional role in a specific cancer.

Instead of following the canonical approach of identifying sets of genes whose expression can separate patients into two groups whose survivorship distributions are maximally 'different' (as measured by the log-rank statistic), our ranking algorithms take a gene-by-gene approach to measuring expression-survival correlation:

- MiRank-A follows a multi-step, non-traditional process that outputs a ranking metric T (for each gene/miRNA) that measures the correlation of differential expression with differential patient survival.
- MiRank-B is essentially MiRank-A, backwards. While MiRank-A orders patients by differential expression, then examines the resultant distribution of survival (across the ordered set of patients), MiRank-B first stratifies patients by differential survival then examines the resultant distribution of differential expression. An expression-survival correlation metric *M* follows from this analysis.
- MiRank-C is simply a univariate Cox regression (with expression misregulation values as covariates) that generates a set of regression coefficients, β , that can be used to rank genes/miRNAs by our expression-survival correlation scheme.

Our ranking scheme can also be extended to the world of microRNAs, short non-coding sequences of RNA that downregulate gene expression through RNA interference. In RNAi, one miRNA can target multiple genes. As such, we are able to examine the relationship between highly ranked miRNAs and highly ranked genes. We are especially interested in showing that the bipartite network of top-ranking genes and miRNAs is densely/sparsely connected, which reflects the efficacy of our ranking pipeline.

To justify our use of novel ranking methods, we compare the predictive power of the prognostic indices constructed by Yoshihara et. al. through 'traditional' expression profile-based methods to that of an index generated by *our* pipeline outputs. We do so by performing a Cox regression on a rank-optimized, 260-gene prognostic index that is defined as follows.

$$I_k = \sum_{i=1}^{260} \beta_i \cdot X_{ik} \tag{1}$$

where X_{ik} is the expression misregulation metric of the ith ranked gene for the kth patient, and β_i is the corresponding regression coefficient. The regression delivers a hazard ratio that measures the correlation between patient survival and our prognostic index.

Though gene/miRNA ranking is sufficient for our specified goal of identifying genes and miRNAs of interest to researchers, we can do more. Genes do not act in isolation, but rather through regulatory networks of gene-product interactions. As such, rank data is more useful to biologists when placed in a pathway-centric context.

We accomplish this contextualization by (1) annotating KEGG Pathways gene-product wiring diagrams with color gradients that reflect the distribution of gene ranks within a pathway, (2) ranking pathways by their proportion of 'high' gene ranks, and (3) showing the enrichment of certain gene ontology (GO) terms in highly/poorly ranked functional groups of genes. Thus, we elucidate the functional roles played by highly ranked genes and miRNAs in tumorigenesis, which encapsulates excessive cell proliferation, migration, angiogenesis, etc.

The homebrew software packages that implement our analysis pipelines were written in Java, developed and tested on Mac OS X, and are freely available at http://code.google.com/p/miranktool. We have included sample inputs and outputs to illustrate the nature of our scripts.

2 Methods

2.1 Expression Misregulation Metric X

We propose the metric X to measure gene/miRNA expression misregulation. X is defined as follows.

$$X_{i} = \log_{10}(|f(\bar{C}_{i}, \bar{N}_{i})|)$$
(2)


where C_i is the set of expression-values (across patients) for the *i*th gene/miRNA in OV (cancer sample set), \bar{C}_i is the mean of set C_i , N_i is the set of expression-values (across patients) for the *i*th gene/miRNA in NC(normal control sample set), and \bar{N}_i is the mean of set N_i . f is defined as follows.

$$f(x,y) = \begin{cases} \frac{x}{y} & : x \ge y \\ -\frac{y}{x} & : x < y \\ 1 & : x = 0 \lor y = 0 \end{cases}$$
(3)


2.2 MiRank-A

2.2.1 Survival Spreads

We begin by ordering the patients in the input TCGA data set by their expression of gene/miRNA X (from least to greatest expression-value).



After ordering, we take iterative "slices," or groupings of patients, according to the following scheme.



We now generate a survival "spread" for each grouping. These "spreads" encapsulate the data necessary to calculate the log-rank statistic Z for each grouping. The log-rank statistic, also known as the Mantel-Cox test statistic, measures the similarity of the survival distributions of two patient groups (group 1 and group 2 in figure 1.2).

Generate survival "spread" for each group	ing (exa	Imple below for a	ottom 20 vs.	top 160)	
interval = 270	interval	num_patients_alive_group_1	num_deaths_group_1	num_patients_alive_group_2	num_deaths_group_
<=>	90	160	7	20	1
figures in corresponding row are recorded using data from	180	150	D	19	0
patients for whom	270	142	5	18	0
180 < max(days_to_death, days_to_last_followup) <= 270	360	131	3	18	2
	430	119	5	15	0
	630	114	5	15	2
num patients alive in succeeding row is calculated by	720	105	4	13	0
subtracting the number of right-censored events (deaths	810	97	1	12	0
and 'last followups') from num_patients_alive in preceding	900	91	5	12	0
row	990	85	4	11	0
	1080	73	10	11	0
	1170	61	3	10	1
	1260	57	3	8	0
	1350	53	2	8	0
	1440	49	4	8	1
	1530	44	3	7	0
	1620	41	2	7	0

After iterating this process across the set of genes/miRNAs \mathbf{X} , we are left with the set of survival spreads \mathbf{S} .

1710

2.2.2 Log-Rank Matrices

Let us consider the survival spread S, which corresponds to a certain grouping of patients according to their expression of gene/miRNA X. With the data encapsulated by S, we may calculate Z, the log-rank statistic that measures the similarity between the survival distributions of groups 1 and 2. Z is defined as follows.

$$Z = \frac{\sum_{j=1}^{J} (O_{1j} - E_{1j})}{\sqrt{\sum_{j=1}^{J} V_j}}$$
(4)


where O_{nj} is the number of right-censored events occurring in group n at time j, E_{nj} is the expected number of right-censored events occurring in group n at time j, and V_j is the variance of the O_j distribution (where $O_j = O_{1j} + O_{2j}$). E_{nj} is defined as follows

$$E_{nj} = O_j \frac{N_{nj}}{N_j} \tag{5}$$

where N_{nj} is the number of patients in group n who have not yet died or been right-censored by time j, and $N_j = N_{1j} + N_{2j}$. V_j is defined as follows

$$V_j = \frac{O_j(\frac{N_{1j}}{N_j})(1 - \frac{N_{1j}}{N_j})(N_j - O_j)}{N_j - 1}$$
(6)

After calculating the log-rank statistic for each survival spread, we compile the Z values corresponding to the survival spreads associated with the gene/miRNA X into a matrix.



After iterating this process across the set of genes/miRNAs \mathbf{X} , we are left with the set of log-rank matrices \mathbf{M} .

2.2.3 Rank Spread

From our set of log-rank matrices M, we may generate the following "rank spread."

gene	max	grouping style (bottom;top)	min	grouping style (bottom;top)	mean	median	>1.96	>2.58
MPO	2.69414	40;550	0.0027628357	90;20	1.0409412	1.0260525	121	4
NOS2A	2.8279285	110;330	0.0029707423	30;410	1.4576112	1.5569885	353	15
NOX1	2.1204355	20;30	3.0830945E-4	110;50	0.7022139	0.60062206	3	0
NOX3	2.2322686	50;30	9.5873815E-4	400;190	0.90940815	0.96858096	11	0
NOX4	3.2543085	60;370	0.18381456	520;70	1.713567	1.7567335	663	133
NOX5	2.3433754	110;30	0.0014420918	440;70	0.8317974	0.831254	28	0
NR2F2	2.142266	110;480	0.0011862807	220;270	0.6040009	0.55641484	4	0
SOD1	2.0539865	30;140	1.1025997E-4	110;210	0.6685362	0.5379441	4	0
SOD2	1.7361692	420;90	4.99713E-4	20;150	0.62345415	0.60242546	0	0
SOD3	1.567376	500;90	6.001532E-4	160;350	0.44674462	0.37339982	0	0

where >1.96 represents the number of log-rank statistics in the matrix (corresponding to a certain gene/miRNA) whose values are greater than 1.96 (likewise for >2.58). Note that when Z > 1.96, p < 0.05, and that when

 $Z > 2.58, \, p < 0.01.$

2.2.4 Expression-Survival Correlation Statistic T

We propose the metric T_i to measure the correlation of patient survival with the expression of the *i*th gene/miRNA. T_i is defined as follows.

$$T_i = max(Z_i) \cdot median(Z_i) \tag{7}$$

where $max(Z_i)$ is the maximum log-rank statistic found in the log-rank matrix of the *i*th gene/miRNA, and $median(Z_i)$ is the median of the log-rank statistics found in the log-rank matrix of the *i*th gene/miRNA.

2.3 MiRank-B

2.3.1 Patient Grouping

We begin by dividing patients into a series of 21 groups, according to the following scheme.

	subgroup A	subgroup B
group 1	$t_{death} < 90 \text{ days} (\sim 3 \text{ months})$	$t_{death} > 90 \text{ days} (\sim 3 \text{ months})$
group 2	$t_{death} < 90 \text{ days} (\sim 3 \text{ months})$	$t_{death} > 180 \text{ days} (\sim 6 \text{ months})$
group 3	$t_{death} < 90 \text{ days} (\sim 3 \text{ months})$	$t_{death} > 365 \text{ days} (\sim 12 \text{ months})$
group 4	$t_{death} < 90 \text{ days} (\sim 3 \text{ months})$	$t_{death} > 1095$ days (~ 36 months)
group 5	$t_{death} < 90 \text{ days} (\sim 3 \text{ months})$	$t_{death} > 1825$ days (~ 60 months)
group 6	$t_{death} < 90 \text{ days} (\sim 3 \text{ months})$	$t_{death} > 3650 \text{ days} (\sim 120 \text{ months})$
group 7	$t_{death} < 180 \text{ days} (\sim 6 \text{ months})$	$t_{death} > 180 \text{ days} (\sim 6 \text{ months})$
group 8	$t_{death} < 180 \text{ days} (\sim 6 \text{ months})$	$t_{death} > 365$ days (~ 12 months)
group 9	$t_{death} < 180 \text{ days} (\sim 6 \text{ months})$	$t_{death} > 1095$ days (~ 36 months)
group 10	$t_{death} < 180 \text{ days} (\sim 6 \text{ months})$	$t_{death} > 1825$ days (~ 60 months)
group 11	$t_{death} < 180 \text{ days} (\sim 6 \text{ months})$	$t_{death} > 3650 \text{ days} (\sim 120 \text{ months})$
group 12	$t_{death} < 365 \text{ days} (\sim 12 \text{ months})$	$t_{death} > 365$ days (~ 12 months)
group 13	$t_{death} < 365 \text{ days} (\sim 12 \text{ months})$	$t_{death} > 1095$ days (~ 36 months)
group 14	$t_{death} < 365 \text{ days} (\sim 12 \text{ months})$	$t_{death} > 1825$ days (~ 60 months)
group 15	$t_{death} < 365 \text{ days} (\sim 12 \text{ months})$	$t_{death} > 3650$ days (~ 120 months)
group 16	$t_{death} < 1095$ days (~ 36 months)	$t_{death} > 1095$ days (~ 36 months)
group 17	$t_{death} < 1095$ days (~ 36 months)	$t_{death} > 1825$ days (~ 60 months)
group 18	$t_{death} < 1095$ days (~ 36 months)	$t_{death} > 3650 \text{ days} (\sim 120 \text{ months})$
group 19	$t_{death} < 1825 \text{ days} (\sim 60 \text{ months})$	$t_{death} > 1825 \text{ days} (\sim 60 \text{ months})$
group 20	$t_{death} < 1825 \text{ days} (\sim 60 \text{ months})$	$t_{death} > 3650 \text{ days} (\sim 120 \text{ months})$
group 21	$t_{death} < 3650 \text{ days} (\sim 120 \text{ months})$	$t_{death} > 3650 \text{ days} (\sim 120 \text{ months})$

Figure 1.1.1

where t_{death} is equivalent to max(days_to_death,days_to_last_followup).

2.3.2 Expression and Correlation Statistics

For each group, we generate the following "expression statistics" across all genes/miRNAs: $min(\mathbf{X})$, $max(\mathbf{X})$, $median(\mathbf{X})$, $mean(\mathbf{X})$, and $\sigma(\mathbf{X})$, where \mathbf{X} is the set of expression values for a given gene/miRNA. This information may later be used for verification/reference.

Additionally, for each group we generate the following "expression-survival correlation statistics" across all genes/miRNAs: $O(A \cup B)$, O(B), O(A), f(B, A), $t_e(B, A)$, $p(t_e)$, $t_u(B, A)$, and $p(t_u)$, where O is the fraction of patients in the parameter-specified subgroup whose expression value falls within the range of expression values in the subgroup they are *not* contained in, f(B, A) is the fold change of expression values from subgroup A to subgroup B, t_e is the student's t-test statistic testing the null hypothesis that the distribution of expression values in subgroup A and subgroup B are equal (assuming equal variance), p is the probability density function for the student's t-test distribution, and t_u is the student's t-test assuming *unequal* variance. O is defined as follows.

$$O(Z) = \frac{|I|}{|k|} \tag{8}$$

where I (subset of subgroup Z) is the set of patients whose expression value falls within the range of expression values in the subgroup they are *not* contained in, and k is the set of patients in group k. f is defined as follows.

$$f(B,A) = \begin{cases} \frac{\bar{X}_B}{\bar{X}_A} & : \bar{X}_B \ge \bar{X}_A \\ -\frac{\bar{X}_A}{\bar{X}_B} & : \bar{X}_B < \bar{X}_A \end{cases}$$
(9)

where \bar{X}_A is the mean expression-value in subgroup A (likewise for \bar{X}_B and subgroup B). t_e is defined as follows.

$$t_e(B,A) = \frac{\bar{X}_B - \bar{X}_A}{\sqrt{\frac{(|B|-1)Var(X_B) + (|A|-1)Var(X_A)}{|B|+|A|-2}}} \sqrt{\frac{1}{|B|} + \frac{1}{|A|}}$$
(10)

 t_u is defined as follows.

$$t_u(B,A) = \frac{\bar{X}_B - \bar{X}_A}{\sqrt{\frac{Var(X_B)}{|B|} + \frac{Var(X_A)}{|A|}}}$$
(11)

p is defined as follows.

$$p(t) = \frac{\Gamma(\frac{\nu+1}{2})}{\sqrt{\nu\pi}\Gamma(\frac{\nu}{2})} \left(1 + \frac{t^2}{\nu}\right)^{-\frac{\nu+1}{2}}$$
(12)

where ν is the degrees of freedom of t, and $\Gamma(n)$ is the Gamma function (Lanczos approximation of (n-1)!). ν is defined as follows.

$$\nu(B,A) = \frac{\left(\frac{Var(X_B)}{|B|} + \frac{Var(X_A)}{|A|}\right)^2}{\left(\frac{Var(X_B)}{|B|}\right)^2 + \left(\frac{Var(X_A)}{|A|}\right)^2}{|B|-1} + \frac{\left(\frac{Var(X_A)}{|A|}\right)^2}{|A|-1}}$$
(13)


		each	group							grou	qı			
	min	max	median	mean	st_dev		overlap(lotal)	overlap(bed)	overlap(good)	fold dhance	studiont's t-test statistic (equal variance)	student's t-test p-value (equal variance)	statistic (uncoubl	student's t-ter p-value Cunequel
1561.2	-2.052	1.38275	-0.399	-0.45464774	0.7518968								variance)	variance)
-PDE	-0.896875	0.9165	0.2311875	0.099383526	0.44974952	1581.2	0.92155863	0.8636364	0.9375	1.1520256	4.148033	3.55441448-4	2.6513946	0.015171879
45	-2.3425	4.162	1.677	1.3338864	1.6081191	2-906	0.9313725	0.8151015	0.9525		0.97492005	0.24408934	5.93802	0.32005273
BG	-2.4115	0.7655	-0.34433332	-0.30387878	0.75263774	A180	0.9411765	0.8636364	0.9625	1.14125	6.7701626	7.220434E-7	5.91602	5.724708E-6
2BP1	-2.3051667	1.5796666	-0.47233334	-0.59028035	0.9828134	A2871	0.8235294	0.90909094	0.8	1.1589355		NoN	1.2357476	NoN
м	-2.5415	1.942	-0.1185	-D.14671592	0.86768496	A2H	0.92156863	0.10903034	0.925	1.1256506	4.7155914	3.04101000-5	2.1169875	0.04433845
ML1	-0.8205	1.676	0.203	0.6639318	0.5005878	A2HL1	0.9117547	0.90909094	0.9125	1.2114767	2.059889	0.050458322	1.1468797	0.20093212
GALT2	-0.3885	1.4205	0.21075	0.20265912	0.3618083	ASGALTZ	0.9313725	0.8636364	0.95	1.1701208	5.2635235	3.399554E-5	5.2075257	3.4504510-5
						A4GALT	0.9411765	0.90909094	0.95	1.0097102		0.09496315	0.79007994	0.28919077
IGALT	-1.3995	2.1726665	0.20333333	0.20200755	0.92645603	A4GNT	0.85294116	0.90909094	0.8375	1.14125	6.7701626	7.220434E-7	5.91602	5.724708E-6
IGNT	-0.0695	0.825	0.321	0.25495455	0.20682602	AAAS	0.89215684	0.8636364	0.9	1.14125	6.7701626	7.220434E-7	5.92602	5.724708E-6
VAS	-1.8385	0.14525	-0.79175	-0.6528636	0.43510425	AACS	0.85294116	0.8181818	0.8625		4.7540545	3.13377E-5	2.2469913	0.034273844
ACS	-1.81025	0.59325	-0.3595	-0.29121593	0.6390167	AADAC AADACL1	0.75431374	0.90903094	0.9125	1.1181545	2.0990305	0.14534065	1.0738496	0.30037874
ADAC	0.21825	6.5625	3.9025	3.2932954	1.4356905	AADACL2	0.9019508	0.90909094	0.9		3.9743268	3.05222640-4	1.6625827	0.10053588
ADACL1	-0.771	1.39875	0.315	0.22618183	0.5000971	AADACL3	0.9019508	0.8636364	0.9125	1.1583537		0.014591828	1.8159872	0.0787005
ADACL2	-1.19575	2.18275	-0.114	-0.11670455	0.77194345	AADACL4	0.9019608	0.90909094	0.9	1.1397516	6.681705	8.533395E-7	5.735996	8.6662395-6
DACL3	-0.266	1.001	0.5335	0.44775005	0.27425955	AADAT	0.9813725	0.90909094	0.9875	1.125094	5.371144	7.31405458-6	2.950279	0.00720165
000000					0.07 100000	AAKL	0.9313725	0.8636364	0.95	1.14125	6.7701626	7.2204348-7	5.93602	5.7247088-6
ADACL4	-1.183	0.692	-0.223	-0.25386363	0.4882048									
DAT	-2.137	0.76525	-0.695625	-0.6379886	0.5616943									
ADAT AKI	-2.137 -0.77458334	0.76525 0.7845	-0.695625 0.32075	-0.6379886 0.2132927	0.5616943 0.3250945									
ADAT AKL	-2.137	0.76525 0.7845 0.90525	-0.695625 0.32075 -0.2	-0.6379886 0.2132927 -0.1295341	0.5616943 0.3250945 0.4474554	ues that li	e within	the rar	nge of e	xpres	sion val	ues obs	erved in	the
ADAT AND OVERIAD OVERIAD OVERIAD OVERIAD OVERIAD	-2.137 -0.77458334 -1.203 (total) <=> f (bad) <=> f (good) <=> fo ange <=> fo 's t-test stat	0.76525 0.7845 0.90525 fraction of not in. fraction o fraction o fraction old chang tistic <=>	-0.699625 0.32075 -0.2 of patients in of patients in of patients e of expres	-0.5379866 0.2132927 -0.1295141 with expres n subgrou in subgrou ssion valu	0.5616943 0.3250945 0.4474564 ession value p A that up B that es from s	 ubgroup l	3 to sub	group A	Ą					
ADAT AMP AMP AMP AMP AMP AMP AMP AMP AMP AMP	-2.137 -0.77458334 -1.205 (total) <=> f (bad) <=> f (good) <=> fo	0.76525 0.7845 0.90525 fraction of inaction of fraction of fraction old chang tistic <=> 8.	-0.699625 0.32075 -0.2 of patients of patients in of patients e of expres tests the r	-0.6379866 0.2132927 -0.1295741 with expression in subgrout in subgrout in subgrout in subgrout	0.5616943 0.250945 0.4474544 ession value p A that up B that es from s nesis that	 ubgroup I the distril	3 to sub oution of	group A	Ą					

2.3.3 Recombination

Now, we reorganize our data tables so that each subgroup's expression statistics may be compared side-by-side in the same spreadsheets.

						'Recon	nbine' exp	pression	statisti	cs						
	1911	***	rates	F 88.1	8,007											
1.14	-226	1.9625	-8.999	4.499/75	0.751.0048											
105	-0.00075	6.9266	0.235.3875	LINISIS	E-+0(4062											
	-2.048	6.262	LAW	1.0106944	Landing											
-	12.05.05	6 (915	-3.9808100	1.08191	E-MARITE											
ar.	-2.385367	1.57940.8	-1.0727208	-6.79(2900)	0.0020234											
	-2.5415	1.942	-108	-8.1497,992	Lechoves											
PL1	-0.895	16%	9.70	6.8535338	6.5H8076											
64/12 64/1	-0.3865	L4005	9.2015	6.20085452	EXCHANGE		min_a	min_b	max_a	max_b	median_a	median_b	mean_a	mean_b	it,dev_a	15,60
LA.1	-1.386	1112003	0.000	1.0000703	LANGER IN	1561.2	-2.052	-2.4525	1.83975	1,757	-0.40775	-0.3245	-0.2918954	-0.33363254	0.6888212	6.729
45	-1.005	1105	4.905	1.0000	1-150703	2-PD6	-8.896875	-1.0155	0.9365	1.4521675	0.1330525	0.0658375	0.07990626	0.050003294	0.17100125	
64	-1.6328	1.00.0	-1.000	1202.00	LAUNDAT	785	2.66	2.0645	4.162	1.013	1.3045	1.0000	1.1100.042	1.1138215	1.4381577	
	1.050	5.7621	1.50	1.01000	Lanese											
NELL	9.00	1,29979	0.30	10000	1.000001	A285	-2.4315	-2.6016067	1.0136666	1.1278334	-0.344333332	-0.4735	-0.31850.038	-0.55435747	0.58920325	6.838
ec.a	-1.19(2)	1.14275	-8.134	410040	0713008	A29P1	-2.3051667	-2.4576666	3.4283333	5.467	-0.946	-0.62233335	-0.5600009	-0.11800723	1.0313999	1.548
NCA	-0.286	LOU	0.505	6.47588	0.27405854	AIM	-2.5415	-2.12925	1.942	3.223	-0.292	-0.902	-0.26586458	-0.44092736	0.8244335	1.652
INCL4	-1.180	6.662	-8.222	4.258000	E-495040	A246.1	-8.8205	-2.8625	2,7665	5.7925	0.703	0.755	0.6290417	0.82390547	0.5452773	
047	-2.159	6.9650	-1.003623	-6.637600	6.561.80×0											
#1.	-0.77458334	6.7843	0.30075	6.2132607	6.3250945	A3GNLT2	-8.44875	-1.3995	1.4285	1.1719000	0.2005	0.1765	0.16296874	0.15717812	0.29813004	
*	-1.2005	198525	-8.8	4.18674	E-017684	ANGALT	-1.3995	-2.0303666	2.5658333	3.44886555	0.9125	0.306	0.1804514	6.3200217	0.87380325	6.909
						ANGINE	-0.4475	-1.7215	0.825	1.8575	0.2995	-0.00225	0.24551.043	-0.5721325	0.1517257	0.514
	100	144	relat	Cash.	6.017	446	1.8385	-1.75625	0.621	1,4005	-0.25825	.0.475	-0.55764536	-0.39931005	0.43560827	0.900
	-2.05	Laters	18,200	1.000/00	6,007	MCD	1.82005	-0.80175	9.99315	0.025	-0.365	3.59625	-0.2143699	3.5667133	0.5500412	1.6630
	0.000	1000	12010	1. PERSONAL	1.0000002	4000	-5.403		6.9625	2.656	3,2425		2.662526		1.5338761	
	-2.005	0.142	1.477	1.00 Miles	3.404(04)			-2.55175				0.06575		0.030151836		6.900
	-2.6.0	1,703	-3.1000000	1.000	1200073	AMDAGL1	-2.00275	-1.66375	2.01275	5.00925	0.9905	-0.0205	0.15329167	0.082291074	0.7006239	0.812
m	2388892	1,529408	1.4727304	4.192805	1002134	AMDAGL2	-1.313	-0.35	2.18275	1.401	-0.117	0.532	-6.00090304	0.5431339	0.4543335	6.319
	12,0405	1.942	10.1203	10.0405.000	18/70/04	AADADJ3	-8.206	-1.4595	1.454	1,8545	0.5635	-0.356	9.43205579	-0.33031566	0.33425574	0.400
P63	-0.8255	L6N6	9.70	6.6620328	1.5105070	44090.4	-1.97	-2.264125	1.4175	1.431625	-0.303	0.645	-0.20422615	-0.514496	0.43228774	
CAUS	-0.3865	L4905	9.2075	6.20265832	10100	AADAT	-2.22575	-0.64836365	0.76525	1.7133234	-0.694125	0.15293996	-6.6244729	0.10335746		
64.7	-1.2965	2173995	0.000000	4.20390735	L KOPORT										0.5546029	
LM.	-0.3865	6.625	0.31	12040403	E 20 MERCE	AAK),	-8.77458334	-1,478	0.84343666	1.825	0.35483333	0.05625	0.22513591	0.071578346	0.28195608	0.557
	-6.0005	6.24525	-1.1605	1.00800	E-65093	AMP	-1.2835	-0.1335	0.90525	1.8865	-0.32675	0.607	-0.02606771	0.61736473	0.43896342	6.325
	-1.0000	0.000	-5.000	- A propriet	Languar .	AANAT	0.1265	-2,7865	1.344	0.38900905	0.3045	-1.320367	9.5023094	-1.2709632	0.2502205	6.322
NRC 11	10.275	1.3675	435	6.2010/001	L-Sector	AARS	-2.2500333	-1.0653067	0.075100000	1.2913333	-1.4535557	-0.23366666	-1.1043507	-0.22259941	0.58589304	
MULT IN CO.	11100	1.000	18.136	1.0308057	0.000001		-2.2000202	* 2. West of all	0.077100000	1.4912.000	1.400000	-0.11100000	12.000.001	-0.222,004.	V. 20000000	
everal everal	2,00	LOU	9,000	1.4172480	5215080											
NCM	1.180	5.60	4.10	4.208000	Lence											
-	-2159	1,2555	-1.929(3)	-1.157606	6.502.0040											
41	-0.7993334	0.045	0.3075	12,2592	0.1020045											

We perform a similar 'recombination' on our expression-survival correlation statistics, so that each statistic is isolated in its own table (and its change across groups is made clear).



2.3.4 Expression-Survival Correlation Statistic M

We propose the metric M_i to measure the correlation of patient survival with the expression of the *i*th gene/miRNA. M_i is defined as follows.

$$M_{i} = \sum_{k=1}^{21} \left(|f(B_{ik}, A_{ik})| \cdot (1 - O_{i}(A_{k} \cup B_{k})) \cdot \frac{lb(B_{k})}{ub(A_{k})} \right)$$
(14)

where $f(B_{ik}, A_{ik})$ is the fold change of expression values of the *i*th gene/miRNA from subgroup A of group kto subgroup B of group k, lb(B) returns the lower bound of survival (in days) in subgroup B, ub(A) returns the upper bound of survival (in days) in subgroup A, and $O_i(A_k \cup B_k)$ is the overlap fraction of the *i*th gene/miRNA in the context of group k ($1 \le k \le 21$).

2.4 MiRank-C

2.4.1 Survival Analysis

The survival function S(t) = Pr(T > t), where Pr is probability and T is the time of death, can be used to describe the survival of a population over time. Given the clinical information days_to_death and

days_to_last_follow_up for each patient in the TCGA data set the input TCGA data set, one can plot a Kaplan-Meier step function that approximates S(t) within specified intervals. Specifically, the KM curve is a plot of $\hat{S}(t)$, the maximum likelihood estimate of S(t), over time. $\hat{S}(t)$ is defined as

$$\hat{S}(t) = \prod_{t_i < t} \frac{n_i - d_i}{n_i} \tag{15}$$

where n_i is the number of survivors less the number of right-censored losses that occur in the input TCGA data set at time t_i , and d_i is the number of deaths that occur in the input TCGA data set at time t_i . Thus, S(t) is associated with the clinical information encapsulated by the input TCGA data set.

The hazard function $\lambda(t) = -\frac{S'(t)}{S(t)}$ describes the instantaneous density of events (deaths and right-censored losses) at time t. The cumulative hazard function $\Lambda(t) = \int_0^t \lambda(u) \, du = -\ln(S(t))$ describes the accumulated hazard from time 0 to time t. Thus, $\Lambda(t)$ is associated with S(t).

2.4.2 Cox Proportional-Hazards Model

The Cox Proportional-Hazards Model allows us to relate certain covariates, or explanatory variables, to the cumulative hazard function through the following parameterization

$$\Lambda(t|\mathbf{X})_{k} = \Lambda_{0}(t)_{k} e^{\beta_{0} X_{0,k} + \beta_{1} X_{1,k} + \beta_{2} X_{2,k} + \dots + \beta_{n} X_{nk}}$$
(16)

where $\Lambda_0(t)_k$ is the baseline hazard function for the *k*th patient, \mathbf{X}_k is the vector of covariates for the *k*th patient, and β is the set of regression coefficients. \mathbf{X}_k is defined as the vector of expression covariates, where X_{ik} is the expression misregulation metric of the *i*th gene/miRNA in the *k*th patient.

Under this relation, covariate X_{ik} has a multiplicative effect proportional to β_i on hazard. Thus, gene/miRNA expression misregulation is associated with patient survival.

2.4.3 Cox Regression

Our goal is to rank genes/miRNAs by the correlation of their expression misregulation with differential patient survival. We accomplish this by estimating the values of the regression coefficients β from equation (16), which can then be used to compare the hazard ratios of genes/miRNAs. First, let us define the following functions.

The partial likelihood function describes the probability of a parameter in an equation like (16) having a certain value given a set of observed data. Partial likelihood is defined as follows

$$L_n(\beta_n) = \prod_t \left(\frac{e^{X_n \beta_n}}{\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t)} \right)^{D(t)}$$
(17)

where t is a discrete unit of time (at which at least one event occurs), **R** is the set of patients still at risk at time t, X_{nk} is the expression misregulation value for the nth gene/miRNA of the kth patient, X_n is the sum of the expression misregulation values of the patients dying at time t, $D_k(t)$ is the probability of the kth patient's death at time t, and D(t) is the number of deaths that occur at time t.

The log partial likelihood, which produces more computationally 'convenient' probability figures than the partial likelihood, is defined as follows

$$l_n(\beta_n) = \ln(L(\beta_n)) = \sum_t \left[D(t) \left(X_n \beta_n - \ln\left(\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t)\right) \right) \right]$$
(18)

Our goal is to find $\hat{\beta}$, the set of maximum partial likelihood estimates (MPLES) for β . To do so, we must find the β_n -values that maximize their log partial likelihood functions $l_n(\beta_n)$.

We maximize $l_n(\beta_n)$ by approximating the roots of its first derivative using Newton's method. This gives us β_n -values that correspond to the extreme points of l_n . The β_n -value that corresponds to the extreme point with the greatest l_n value will be our MPLE.

The partial score function is defined as follows.

$$l'_{n}(\beta_{n}) = \sum_{t} \left[D(t) \left(X_{n} - \frac{\sum_{k \in \mathbf{R}} X_{nk} e^{X_{nk} \beta_{n}} D_{k}(t)}{\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_{n}} D_{k}(t)} \right) \right]$$
(19)

The first derivative of the partial score function (second derivative of $l_n(\beta_n)$) is defined as follows.

$$l_n''(\beta_n) = -\sum_t D(t) \left[\frac{\sum_{k \in \mathbf{R}} X_{nk}^2 e^{X_{nk}\beta_n} D_k(t)}{\sum_{k \in \mathbf{R}} e^{X_{nk}\beta_n} D_k(t)} - \left(\frac{\sum_{k \in \mathbf{R}} X_{nk} e^{X_{nk}\beta_n} D_k(t)}{\sum_{k \in \mathbf{R}} e^{X_{nk}\beta_n} D_k(t)} \right)^2 \right]$$
(20)

Newton's method, also called the Newton-Raphson algorithm, for approximating the zeroes of a univariate function f(x) is described by the following recursive relation

$$x_{n+1} = x_n - \frac{f(x_n)}{f'(x_n)}$$
(21)

Applying Newton's method to the approximation of the roots of the partial score function, we find that

$$\beta_{n,k+1} = \beta_{n,k} - \frac{l'(\beta_{n,k})}{l''(\beta_{n,k})}$$

$$\tag{22}$$

where $\beta_{n,k}$ is the *k*th iteration on the value β_n . After applying this recursive relation to each value in β , we are left with our set of MPLEs $\hat{\beta}$.

2.4.4 Gradient Descent with Modification

Although the convergence rate of Newton's method is fairly high, reducing the computational complexity of MiRank-C, the log partial likelihood function does not conform to *all* the preconditions of the Newton-Raphson algorithm. Because the partial score function is discontinuous, Newton's method can sometimes encounter an x-value outside the likelihood function's continuous interval, causing the recursive relation to 'diverge' permanently. For this reason, we must modify our approach to approximating the zero of the partial score function.

We propose a 'gradient descent with modification' approach to approximating the zero of the partial score

function for β_n values that 'escape' the likelihood function's interval of continuity during an iteration of Newton's method. The algorithm is as follows on the next page.

2.5 Pathway Profiling

2.5.1 Consolidated Rank α

To simplify our enrichment analyses, we propose the following 'consolidated' rank α .

$$\alpha_i = \frac{Z(\beta_i) + Z(M_i) + Z(T_i) + Z(X_i)}{4}$$
(23)

where Z is the normalization function defined as follows.

$$Z(Y_i) = \frac{Y_i - \bar{Y}}{\sigma(\mathbf{Y})} \tag{24}$$

where \bar{Y} is the mean of set **Y**, and $\sigma(\mathbf{Y})$ is the standard deviation of set **Y**.


2.5.2 KEGG Pathway Enrichment

With our set of ranks α , we can now take gene classes defined in KEGG Pathways (i.e. Ubiquitin-mediated Proteolysis Pathway, p53 Signaling Pathway, etc.) and calculate Fisher's one-sided exact test statistic τ for each. This figure ranks each pathway by the proportion of occurrences of "high" ranks in its gene/miRNA class against the occurrences of "high" ranks in *all* genes being considered. τ is defined as follows.

$$\tau_i = \frac{\frac{|G_P|}{|P_i|}}{\frac{|G_X|}{|\mathbf{X}|}} = \frac{|G_P|}{|G_X|} \cdot \frac{|\mathbf{X}|}{|P_i|}$$
(25)

where **P** is the set of genes implicated in the *i*th pathway, **X** is the vector of genes/miRNAs under consideration, G_P is the subset of **P** for which $\alpha_n \geq \bar{\alpha}$, and G_X is the subset of **X** for which $\alpha_n \geq \bar{\alpha}$.

 τ_i now represents the enrichment of the *i*th pathway with highly ranked genes.



2.5.3 Clustering

We cluster using a self-organizing map (SOM), a method that produces clusters that are more "stable" but less "compact" than those produced by k-means partitioning, partitioning around medoids, etc. The algorithm is as follows.

- 1. Let $\mathbf{x}_i : \{\beta_i, M_i, T_i, X_i\}$ be the vector associated with the *i*th gene/miRNA.
- 2. Randomly choose a sample vector \mathbf{x} from the input data set.
- 3. Find the gene/miRNA whose vector minimizes the following

$$||\mathbf{x} - \mathbf{m}_b|| = \min_i \{||\mathbf{x} - \mathbf{m}_i||\}$$
(26)

where \mathbf{m}_i is the vector associated with the *i*th gene, *b* denotes the best-matching unit (BMU), and $||\mathbf{a} - \mathbf{b}||$ represents the Euclidean distance between \mathbf{a} and \mathbf{b} .

4. Update gene/miRNA vectors (excepting the BMU) according to the following rule.

$$\mathbf{m}_{i}(t+1) = \mathbf{m}_{i}(t) + \alpha(t)h_{bi}(t)[\mathbf{x} - \mathbf{m}_{i}(t)]$$
(27)

where t is time, α is the learning rate, and h_{bi} is the neighborhood kernel centered on the BMU. $\alpha(t)$ is defined as follows.

$$\alpha(t) = \frac{1}{1 + \ln(t)} \tag{28}$$

 h_{bi} is defined as follows.

$$h_{bi}(t) = \exp\left(-\frac{||\mathbf{m}_b - \mathbf{m}_i||}{2\sigma^2(t)}\right)$$
(29)

where $\sigma(t)$ is defined as follows.

$$\sigma(t) = \frac{1}{1 + \ln(t)} \tag{30}$$

5. Repeat steps 2-4 until $\alpha < 0.25$

2.5.4 Partitioning

After clustering with an SOM, we apply hierarchical agglomerative clustering to the resultant set of vectors, thus assigning each gene/miRNA to a discrete partition in a series of "levels." The algorithm is as follows.

- 1. Place each sample vector from the input data set into its own singleton partition.
- 2. Merge the two closest partitions. The distance between a partition A and partition B is defined as follows.

$$d(A,B) = \frac{1}{|A||B|} \sum_{i \in A} \sum_{j \in B} ||i - j||$$
(31)

- 3. Add the current set of partitions to level k, where k is the distance between the two closest partitions from step 2.
- 4. Repeat steps 2 and 3 until all the data are merged into a single partition.

After judicious analysis of pipeline outputs, one may select a set of partitions with an 'appropriate' magnitude of separation.

2.5.5 GO Term Enrichment

After delineating partitions, we generate a spread of GO terms associated with the genes in each partition. Additionally, we show the relative frequencies of occurrences of GO terms within each partition. Gene:Term associations were found using data from ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/HUMAN/. Term descriptions were also web-scraped from http://www.ebi.ac.uk/QuickGO.

3 Results

3.1 Gene/miRNA Ranking

gene	Consolidated Rank (Alpha)	miR	Consolidated Rank (Alpha)
TCF7	6.4270535	hsa-miR-34c-3p	5.2762966
RPS6KA2	2.3743002	hsa-miR-139-5p	2.2229412
SOCS2	1.99857	hsa-miR-133a	2.1366444
TNFRSF4	1.9086596	hsa-miR-34c-5p	2.0398793
LAMB2	1.7359532	hsa-miR-155	1.4723357
CCND2	1.6566322	hsa-miR-515-5p	1.4626533
FZD5	1.5173668	hsa-miR-486-5p	1.3781605
СНР	1.4788748	hsa-miR-449a	1.3206564
CCR7	1.418112	hsa-miR-938	1.2998003
RALA	1.3220334	hsa-miR-211	1.2449175
CCL3	1.2700129	hsa-miR-604	1.2163122
TNFRSF10B	1.2098999	hsa-miR-890	1.1966283
CXCL9	1.203721	hsa-miR-455-5p	1.1835667
DTX3L	1.1925004	hsa-miR-34b	1.1783645
FZD10	1.1643226	hsa-miR-142-3p	1.1649697
CD27	1.1547524	hsa-miR-146a	1.123212
MMP9	1.1547232	hsa-miR-504	1.1161133
CHP2	1.1415317	hsa-miR-519d	1.1075377
IL5RA	1.1056126	hsa-miR-96	1.0646632
TBL1XR1	1.0584645	hsa-miR-632	0.9008667

Top 20 Genes/miRNAs, by Rank

3.2 Prognostic Index Performance Comparison

The 260-gene prognostic index constructed from the outputs of our ranking pipeline achieved a hazard ratio of 1.15 (a 1 unit increase in a patient's prognostic index corresponds to a 1.15x increase in a patient's 'hazard', or risk of death). Yoshihara et. al. reported an HR of 1.62 for their genetic profile-based survival index (applied to Tothill's data set of serous ovarian cancer patients).

3.3 Pathway Profiling

pathway	kegg_id	tau	lg_pl	P	lg_xl	X
Wnt signaling pathway - Homo sapiens (human)	4310	1.0864226	68	146	463	1080
Notch signaling pathway - Homo sapiens (human)	4330	1.0849365	20	43	463	1080
Pathways in cancer - Homo sapiens (human)	5200	1.0835366	144	310	463	1080
VEGF signaling pathway - Homo sapiens (human)	4370	1.0513186	32	71	463	1080
MAPK signaling pathway - Homo sapiens (human)	4010	1.048772	116	258	463	1080
Apoptosis - Homo sapiens (human)	4210	1.036717	36	81	463	1080
Focal adhesion - Homo sapiens (human)	4510	1.0312606	84	190	463	1080
TGF-beta signaling pathway - Homo sapiens (human)	4350	1.0299851	34	77	463	1080
Cytokine-cytokine receptor interaction - Homo sapiens (human)	4060	1.0175186	106	243	463	1080
Hedgehog signaling pathway - Homo sapiens (human)	4340	0.9996915	24	56	463	1080
Jak-STAT signaling pathway - Homo sapiens (human)	4630	0.9950309	61	143	463	1080
Cell cycle - Homo sapiens (human)	4110	0.9908446	48	113	463	1080
p53 signaling pathway - Homo sapiens (human)	4115	0.8412704	22	61	463	1080


Pathway Enrichment

The following gene-product wiring diagrams were taken from the KEGG Pathways database and annotated (coloured) by our scripts.

4 Discussion

4.1 Ontology Overview of Top-Ranking Pathways

- The Wnt signaling pathway plays a significant role in cell-fate specification and progenitor-cell proliferation, which is significantly upregulated in cancerous germ line cells that give rise to (ovarian) epithelial cells.
- Activation of the VEGF signaling pathway leads to the upregulation of genes involved in mediating the proliferation and migration of endothelial cells and promoting their survival and vascular permeability, a key attribute of tumorigenic cells.
- The MAPK signaling pathway regulates critical cellular functions like proliferation, differentiation, and migration: functions whose misregulation is associated with cancer.
- The Notch signaling pathway encodes the processes necessary for intercellular signaling, which is necessary for tumorigenesis and cell migration (metastasis).
- Apoptosis, or programmed cell death, is often suppressed once a cell undergoes carcinogenesis.



A gradient (passing through dark gray for values near the mean) separates low-ranking genes, in bright green, from high-ranking genes, in bright red.

						canonical Wnt receptor signaling pathway (3)							canonical Wnt receptor signaling pathway (3)					
							to Ine											
						integral to membrane (3)	integral to membrane (3)						cell surface (4)					
			regulation of apoptotic process (2)			cell surface (4)	external side of plasma membrane (2)		immune response (4)				brain development (2)				integral to membrane (3)	
			cell surface (4)			brain development (2)	immune response (4)		inflammatory response immune response (3) (4)		external side of plasma membrane (2)		integral to plasma membrane (2)	response to ethanol (2)			membrane (3)	
canonical Wnt receptor signaling pathway (3)			external side of plasma membrane (2)		response to ethanol (2)	plasma membrane (6)	inflammatory response (3)	membrane (3)	chemotaxis (3)	regulation of apoptotic process (2)	signal transduction (4)		plasma membrane (6)	membrane (3)	٤	3	signal transduction (4)	
regulation of apoptotic process (2)			immune response (4)		response to estradiol stimulus (2)	cytoplasm (8)	chemotaxis (3)	cell surface (4)	cytosol (4)	integral to membrane (3)	immune response (4)		cytoplasm (8)	cell surface (4)	response to ethanol (2)		plasma membrane (6)	
brain development (2)	signal transduction (4)	response to estradiol stimulus (2)	inflammatory response (3)		membrane (3)	protein binding (11)	plasma membrane (6)	signal transduction (4)	cytoplasm (8)	signal transduction (4)	Inflammatory response (3)		protein binding (11)	integral to plasma membrane (2)	response to estradiol stimulus (2)		receptor activity (7)	
nucleus (4) immune response (4)	cytosol (4)	cytosol (4)	integral to plasma membrane (2)		cytosol (4)	G-protein coupled receptor activity (2)	G-protein coupled receptor activity (2)	chemotaxis (3)	extracellular space (3)	plasma membrane (6)	chemotaxis (3)	cytoplasm (8)	G-protein coupled receptor activity (2)	extracellular region (4)	extracellular space (3)		extracellular space (3)	canonical Wnt receptor signaling pathway (3)
nucleus (4)	cytoplasm (8)	cytoplasm (8)	plasma membrane (6)		cytoplasm (8)	receptor activity (7)	receptor activity (7)	plasma membrane (6)	extracellular region (4)	protein binding (11)	extracellular space (3)	nucleus (4)	receptor activity (7)	protein binding (11)	extracellular region (4)		protein binding (11)	nucleus (4)
protein binding (11)	nucleus (4)	protein binding (11)	receptor activity (7)	extracellular region (4)	nucleus (4)	signal transducer activity (2)	signal transducer activity (2)	protein binding (11)	protein binding (11)	receptor activity (7)	extracellular region (4)	protein binding (11)	signal transducer activity (2)	receptor activity (7)	protein binding (11)	cytoplasm (8)	receptor activity (7)	protein binding (11)
TCF7	RPS6KA2	SOCS2	TNFRSF4	LAMB2	CCND2	FZD5	CCR7	RALA	CCL3	TNFRSF10B	CXCL9	DTX3L	FZD10	CD27	6dWW	CHP2	ILSRA	TBLIXR1

4.2 Ontology of Top-Ranking Genes

Gene: Associated GO Terms (# occurrences of term in table)

Highlight: Several genes in our top-20 set are ontologically involved in the canonical Wnt receptor signaling pathway (highly enriched, by τ), which regulates key functions like cell-fate specification and progenitor-cell proliferation.

hsa-miR-34c-3p										
hsa-miR-139-5p	JUN (26)	FOS (138)	SOCS2 (4)	ITGA3 (27)	RAP1B (96)					
hsa-miR-133a	PPP2CB (54)	TNFRSF10B (13)	EGFR (25)	PPP2R5E (124)	SP1 (66)	ID4 (41)	TGFBR1 (148)	CHP (9)		
hsa-miR-34c-5p	IL6R (106)									
hsa-miR-155	SP1 (66)	FOS (138)	KRAS (69)	FZD5 (8)	CBL (105)	YWHAZ (87)	SPI1 (74)	SOS1 (86)	RAP1B (96)	ARRB2 (47
hsa-miR-515-5p	BMP8B (56)	PIK3CG (145)	RAP1B (96)	GADD45B (24)						
hsa-miR-486-5p										
hsa-miR-449a	NUMBL (103)	TBL1XR1 (21)								
hsa-miR-938	YWHAZ (87)	SPRED2 (79)	E2F3 (94)							
hsa-miR-211	VHL (107)									
hsa-miR-604										
hsa-miR-890	CHP (9)									
hsa-miR-455-5p	SOCS3 (114)	NLK (92)	FZD5 (8)	TBL1XR1 (21)						
hsa-miR-34b	ITGA2 (82)	TGFA (29)								
hsa-miR-142-3p	TGFBR1 (148)	PPP3CA (93)								
hsa-miR-146a										
hsa-miR-504	RAP1B (96)									
hsa-miR-519d										
hsa-miR-96	KRAS (69)	BCR (113)	PPP3CA (93)	NF1 (77)	SOS1 (86)	CCND2 (7)	FGF9 (99)			
hsa-miR-632	RAPGEF1 (112)	NTRK2 (127)	TRAF4 (147)							

4.3 Oncogenic Targets of Top-Ranking miRNAs

miRNA: Gene Targets (Position on list, sorted by rank)

4.4 Intra-pathway "Driver" Genes

Functional groups of genes mentioned below are highly ranked within their respective pathways (and are coloured red in their annotated KEGG diagrams).

Pathways in Cancer (KEGG 05200): (1) upregulation of TCF leads to evasion of apoptosis, programmed cell death; (2) upregulation of Wnt leads to excessive cell proliferation; (3) upregulation of VEGF, Jun and Fos leads to sustained angiogenesis, which provides nourishment for the growing tumor.

Apoptosis (KEGG 04210): (1) downregulation of Cn leads to downregulation of one of the Ca2+-induced Cell Death Pathways involved in apoptosis; (2) downregulation of CASP8 leads to the downregulation of dna fragmentation and cell degradation.

MAPK Signaling Pathway (KEGG 04010): (1) upregulation of Fos leads to excessive cell proliferation and differentiation (in germ lines); (2) upregulation of NFkB leads to cell proliferation, inflammation and anti-apoptosis.

5 Conclusion

The outputs of our analysis pipeline support our hypothesis that the expression-survival correlation scheme described in Section 2 can be used to rank and identify genes/miRNAs that play critical roles in ovarian carcinoma.

- Several top-ranking functional groups of genes (Wnt, VEGF, Jun, Fos, etc.) are already known to be involved in tumorigenesis.
- Several miRNAs in our top-20 set (sorted by rank) have targets in the top two quartiles of genes.
- The misregulation of highly-ranked genes in enriched pathways drives excessive cell proliferation, migration, angiogenesis, etc., which are characteristic of ovarian carcinoma.

Researchers now have at their disposal a series of open-source scripts that can be used to screen TCGA and KEGG data sets for genes/miRNAs and pathways of 'interest' in a given cancer.

The hazard ratio of our prognostic index was slightly below those reported by Yoshihara et. al. As such, to improve our experimental procedure, we could closely examine our ranking scheme and perhaps expand its scope. As described in Section 2, our pipeline takes only expression data and clinical information as inputs. Integrating other genomic characterizations of ovarian cancer provided by TCGA, like copy-number aberrations and dna methylation irregularities, into MiRank-A/B/C could improve the performance of our prognostic index, and thus, the selectiveness of our gene/miRNA ranking.

In examining the outputs of CBioKonnect (http://sourceforge.net/projects/cbiokonnect/), a data visualization tool we developed last summer, we found that several genes (including p53, a tumor suppressor that is typically downregulated in cancer) are heavily mutated in ovarian carcinoma, but seem to have 'normal' expression levels according to TCGA and CBioPortal data. This is most likely because the oligonucleotide probes in most expression microarrays are not designed to measure the up/down-regulation of genes that occurs due to mutation.

This masking of the 'true' expression levels of genes like p53 highlights a deficiency in our analysis pipeline: a reliance on 'incomplete' expression data from TCGA. If we were to calculate the effective expression levels of genes/miRNAs rather than rely solely on TCGA microarray data, I'm sure we would find many more of them to be misregulated (and thus, more highly ranked).

The results of our pathway-centric profiling of TCGA data sets lead us to wonder how cancer has evolved to target such a diverse range of genes and miRNAs, especially those that regulate critical cellular functions. If protein-protein interaction networks are as robust as most quantitative biology studies claim, how is it that a single disease can misregulate several pathways to such an extent that a cell becomes cancerous? Examining the topology of the network of genes/miRNAs targeted by various cancers and showing that it reflects an optimal selection of network nodes to misregulate (in order to accomplish excessive cell proliferation, migration, etc.) would highlight key elements of cancer's "network of misregulation" and allow researchers to design drugs that target genes/miRNAs that act as "drivers" of misregulated cellular activity.

References

- [1] SOM Toolbox for Matlab 5.
- [2] Fundamentals of Artificial Neural Networks. MIT Press, 1995.
- [3] An R and S-PLUS Companion to Applied Regression, chapter Appendix: Cox Proportional-Hazards Regression for Survival Data. Sage Publications, Inc, 2002.
- [4] David M. Blei. Hierarchical clustering. Lecture Slides, February 2008.
- [5] Elizabeth R. Brown. Cox proportional hazards models. Lecture Slides, March 2004.
- [6] Gengxin Chen, Saied A Jaradat, Nila Banerjee, Tetsuya S Tanaka, Minoru S H Ko, and Michael Q Zhang. Evaluation and comparison of clustering algorithms in analyzing es cell gene expression data. *Statistica Sinica*, 12(1):241262, 2002.
- [7] Anne P. G Crijns, Rudolf S. N Fehrmann, Steven de Jong, Frans Gerbens, Gert Jan Meersma, Harry G Klip, Harry Hollema, Robert M. W Hofstra, Gerard J. te Meerman, Elisabeth G. E de Vries, and Ate G. J van der Zee. Survival-related profile, pathways, and transcription factors in ovarian cancer. *PLoS Med*, 6(2):e1000024, 02 2009.
- [8] R. K. Gaire, J. Bailey, J. Bearfoot, I. G. Campbell, P. J. Stuckey, and I. Haviv. MIRAGAA–a methodology for finding coordinated effects of microRNA expression changes and genome aberrations in cancer. *Bioinformatics*, 26:161–167, Jan 2010.
- [9] H. Kim, W. Huang, X. Jiang, B. Pennicooke, P. J. Park, and M. D. Johnson. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. *Proc. Natl. Acad. Sci. U.S.A.*, 107:2183–2188, Feb 2010.
- [10] Panagiotis A Konstantinopoulos, Dimitrios Spentzos, and Stephen A Cannistra. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Prac Oncol, 5(10):577–587, 10 2008.
- [11] Professor Pier Luca Lanzi. Clustering: Partitioning methods (machine learning and data mining). Lecture Slides.
- [12] Parminder K. Mankoo, Ronglai Shen, Nikolaus Schultz, Douglas A. Levine, and Chris Sander. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. *PLoS ONE*, 6(11):e24709, 11 2011.
- [13] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 474:609–615, Jun 2011.
- [14] Sujaya Srinivasan, Irene Rosita Pia Patric, and Kumaravel Somasundaram. A ten-microrna expression signature predicts survival in glioblastoma. *PLoS ONE*, 6(3):e17438, 03 2011.
- [15] Xuan Bich Trinh, Wiebren A. A. Tjalma, Luc Y. Dirix, Peter B. Vermeulen, Dieter J. Peeters, Dimcho Bachvarov, Marie Plante, Els M. Berns, Jozien Helleman, Steven J. Van Laere, and Peter A. van Dam. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. *PLoS ONE*, 6(7):e22469, 07 2011.

- [16] Marc J. van de Vijver, Yudong D. He, Laura J. van 't Veer, Hongyue Dai, Augustinus A.M. Hart, Dorien W. Voskuil, George J. Schreiber, Johannes L. Peterse, Chris Roberts, Matthew J. Marton, Mark Parrish, Douwe Atsma, Anke Witteveen, Annuska Glas, Leonie Delahaye, Tony van der Velde, Harry Bartelink, Sjoerd Rodenhuis, Emiel T. Rutgers, Stephen H. Friend, and Ren Bernards. A gene-expression signature as a predictor of survival in breast cancer. *New England Journal of Medicine*, 347(25):1999– 2009, 2002.
- [17] Juha Vesanto and Esa Alhoniemi. Clustering of the self-organizing map. IEEE Transactions on Neural Networks, 2000.
- [18] Kosuke Yoshihara, Atsushi Tajima, Tetsuro Yahata, Shoji Kodama, Hiroyuki Fujiwara, Mitsuaki Suzuki, Yoshitaka Onishi, Masayuki Hatae, Kazunobu Sueyoshi, Hisaya Fujiwara, Yoshiki Kudo, Kohei Kotera, Hideaki Masuzaki, Hironori Tashiro, Hidetaka Katabuchi, Ituro Inoue, and Kenichi Tanaka. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. *PLoS ONE*, 5(3):e9615, 03 2010.
- [19] J. X. Yu, A. M. Sieuwerts, Y. Zhang, J. W. Martens, M. Smid, J. G. Klijn, Y. Wang, and J. A. Foekens. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. *BMC Cancer*, 7:182, 2007.
- [20] Dr. Daowen Zhang. Analysis of survival data. Lecture Notes, Spring 2005.